Costs for Acute Myocardial Infarction in a Tertiary Care Centre and Nationwide in France
Tóm tắt
Objective: We compared the estimated costs of coronary interventions from our hospital’s cost accounting system with data from the French Diagnosis Related Group (DRG) cost database, taking the perspective of our hospital.
Design: Cost data on hospital resources used by patients hospitalised for acute myocardial infarction (MI), with and without complications, including deceased patients, were collected in a tertiary care university hospital located in Paris, France. The data were collected using the hospital’s cost accounting system and then compared with the estimates provided by the DRG reimbursement schedule for similar conditions.
Main outcome measures and results: The estimated costs were 849 euro (EUR) for coronary angiography, EUR4762 for coronary angioplasty with stenting, and EUR4978 to 8067 for MI. The DRG reimbursement schedule provided for acute MI was EUR3920 to 5709.
Conclusions: Although the current cost of treating acute MI in a teaching hospital is reasonably close to that in the current reimbursement schedule, rapid technological changes regarding both drugs and devices renders necessary a close monitoring of costs associated with the management of these acute care patients.
Tài liệu tham khảo
Fielding J, Lancry P-J. Lessons from France: ‘vive la différence’. JAMA 1993; 270: 748–56
Drummond M, Stoddart G, Torrance G. Checklist of questions to ask when undertaking an economic evaluation. In: Methods for economic evaluation of health care programmes. Oxford: Oxford University Press, 1996: 35–8
Russel LB, Gold MR, Siegel JR, et al., for the Panel on Cost- Effectiveness in Health and Medicine. The role of costeffectiveness analysis in health and medicine. JAMA 1996; 276: 1172–7
Weinstein MC, Siegel JE, Gold MR, et al., for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations of the Panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253–8
Siegel JE, Weinstein MC, Russel LB, et al., for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations for reporting cost-effectiveness analyses. JAMA 1996; 276: 1339–41
Haas B, Arveiler D, Cambou JP, et al. Prise en charge thérapeutique de l’infarctus du myocarde: évolution dans le projet MONICA-France entre 1985 et 1991. Rev Epidemiol Sante Publique 1996; 44 Suppl. 1: 53–61
Tunstall Pedoe H. Monitoring trends in cardiovascular disease and risk factors: the WHO MONICA project. WHO Chron 1985; 39: 3–5
Rabilloud M, Ecochard R, Myard A-F, et al. Impact du mode de recueil des données sur le classement médico-économique des séjours pour infarctus du myocarde aux Hospices Civils de Lyon. Arch Mal Coeur 1998; 91: 709–14
Jacobzone S, Dormont B, Durand-Zaleski I. Determinants and consequences of technological change in health care in France: heart attacks. In: McClelland M, editor. Technological change in health care. Chicago (IL): Michigan University Press. In press
Mark D, Talley D, Topol E, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for the prevention of high-risk coronary angioplasty. Circulation 1996; 94: 629–35
Mark D, Hlatky M, Califf R, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418–24
Organisation for Economic Co-operation and Development (OECD). The reform of health care systems: a review of seventeen OECD countries. Paris: OECD Publications, 1994
Robinson JC, Garnick DW, McPhee SJ. Market and regulatory influences on the availability of coronary angioplasty and bypass surgery in US hospitals. N Engl JMed 1987; 312: 85–90
Romeo AA, Wagner J, Lee RH. Prospective reimbursment and the diffusion of new technologies in hospitals. J Health Econ 1984: 3; 1–24
Colin C, Ecochard R, Delahaye F. Data quality in a Diagnosis Related Group-based information system. Int J Qual Health Care 1994; 6: 275–80